유투바이오
Financials
Valuation Metrics
유투바이오's Market Cap is ₩518B. At end of 2025 it was ₩640B. Ranked #1661 of 2,410 in KR market (top 69%), #993 of 1,631 on KOSDAQ (top 61%), #66 of 94 in Health Care Equipment & Services (top 70%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 51.81B KRW | KR#1,661/2,410 Sec#66/94 |
| Revenue | 32.14B KRW | KR#2,002/2,410 Sec#62/94 |
| Net Income | -5.72B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 78.02B KRW | KR#1,944/2,410 Sec#63/94 |
| Net Assets | 60.36B KRW | KR#1,785/2,410 Sec#55/94 |
| Employees | 101 | KR#1,624/2,410 Sec#58/94 |
| Value | ||
| P/B | 0.86x | KR#1,443/2,410 Sec#37/94 |
| P/S | 1.61x | KR#1,763/2,410 Sec#48/94 |
| FCF Yield | -3.19% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | -9.47% | KR#1,925/2,410 Sec#66/94 |
| ROA | -7.33% | KR#2,021/2,410 Sec#71/94 |
| Op. Margin | -11.16% | KR#2,008/2,410 Sec#65/94 |
| Revenue Growth | 27.81% | KR#413/2,410 Sec#22/94 |
| Financial Health | ||
| Debt Ratio | 29.27% | KR#565/2,410 Sec#30/94 |
| Total Debt | 640.0M KRW | KR#1,982/2,410 Sec#78/94 |
| FCF | -1.65B KRW | KR#1,313/2,410 Sec#39/94 |
| Cash | 10.12B KRW | KR#1,684/2,410 Sec#54/94 |
| Current Ratio | 2.84x | KR#595/2,410 Sec#36/94 |
| Dividend | ||
| Div. Yield | 3.10% | KR#668/2,410 Sec#12/94 |
| Div. Growth | 60.00% | KR#201/2,410 Sec#11/94 |
| Performance | ||
| 1Y Return | -9.29% | KR#739/2,410 Sec#18/94 |
| 1M Return | -16.23% | KR#1,258/2,410 Sec#45/94 |
| From 52W High | -90.32% | KR#2,393/2,410 Sec#94/94 |
| 1Y MDD | -88.74% | KR#2,383/2,410 Sec#93/94 |
| Trading | ||
| Volume | 9,111 shares | KR#1,770/2,410 Sec#74/94 |
| Trading Value | 29.2M KRW | KR#1,832/2,410 Sec#74/94 |
| Foreign Own. | 2.68% | KR#1,391/2,410 Sec#49/94 |
| Per Share | ||
| EPS | -350 KRW | KR—/2,410 Sec—/94 |
| BPS | 3,699 KRW | KR#1,738/2,410 Sec#46/94 |
Company Info
Established in 2009, this company was listed on the KONEX market in 2015 and transferred to the KOSDAQ market in 2023. It operates in vitro diagnostic testing services and medical IT solutions, collecting specimens from hospitals and clinics nationwide through directly managed stores and agencies, and delivering analysis results via partner medical institutions. The company is pursuing pharmaceutical clinical services with partner medical institutions and U2Biome, an NGS-based personalized health management solution, as new growth engines. U2Bio was established in 2009 and is headquartered in Songpa-gu, Seoul Metropolitan City.